Zenith Epigenetics Corp. closed a $24.56 million private placement with its lead investor, Eastern Capital Ltd., by pricing 24.56 million common shares at $1 apiece. For starters, the funds will finance a phase I trial of the company's pan selective BET (bromodomain and extraterminal domain) inhibitor, ZEN-3694, in the lead indication of metastatic castrate-resistant prostate cancer (mCRPC).